Table of Contents

ABSTRACT

Several decades of progress in lipid-lowering therapy have failed to cause adequate reduction in low-density lipoprotein cholesterol (LDL-C) level. It is still challenging, especially in patients with known or at high risk for cardiovascular disease (CVD) due to presence of atherosclerosis [1]. In these cases, statin therapy alone is often insufficient to cause appropriate reduction of CVD risk [2]. It seems that 7 to 29% of patients report adverse musculoskeletal effects which prevent them from using statins or limit their ability to receive guideline-recommended doses [2-4]. Withdrawal from statin therapy is associated with an increased risk of adverse cardiovascular events [4].